...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Preview Part II....

Led,

A few more comments if there is still time.

First....you wrote "Obviously Cardiovascular disease is a major concern for those with Diabetes, especially those with Diabetes Mellitus which is simply the scientific term for those with full blown insulin dependent diabetes.  Most often its simply referred to as Diabetes." This isn't entirely true. There is Diabetes Mellitus Type 1 and Type 2. Type 1 results from the pancreas's failure to produce enough insulin and Type 2 begins with insulin resistance, a condition in which cells fail to respond to insulin properly, and may progress to insulin insufficiency with severe insulin resistance.

Also, I sugguest you include more BETonMACE details:

1) BETonMACE trial is still enrolling, and reached 1200 of its 2400 target enrollment as of the last update March 2017.

2) Target is 3-point MACE (non-fatal heart attack, non-fatal stroke, cardiovascular death)

3) There is a futility analysis at 125 MACE events that is expected to occur sometime H2 2017

4) The trial is expected to complete enrollment in 2017 and to end in 2018 once it reaches 250 MACE events.

BDAZ

 

Share
New Message
Please login to post a reply